Please login to the form below
Medivir
This page shows the latest Medivir news and features for those working in and with pharma, biotech and healthcare.
RNA-focused biotech Storm Therapeutics raises extra £14m
Previously director of biology at Medivir, Albetella has a successful track record in oncology drug discovery and development at Argenta, OSI Pharmaceuticals, Kudos and AstraZeneca.
Latest news
-
New leader at Medivir after setbacks
Lind leaves the company after just 18 months in the job, and according to Medivir the changeover is intended to help the company “concentrate its activities on clinical development.”. ... Along with remetinostat, Medivir’s clinical pipeline
-
Merck decision to drop odanacatib lifts UCB/Amgen
Ono Pharmaceutical was also developing a drug in the class called ONO-5334 but pulled the programme in 2012 without giving reasons for the decision, while Medivir discontinued its MIV 701
-
The end of hepatitis C?
simeprevir. J&J/Medivir. marketed. bocepravir. Merck &Co. discontinued. asunepravir. BMS. III. vaniprevir.
-
Hepatitis C therapies: dawn of a new age
In 2013, the approvals of the HCV NS3/4A protease inhibitor simeprevir (Olysio; Medivir, Janssen) and the HCV NS5B inhibitor sofosbuvir (Sovaldi; Gilead) signalled the beginning of a new wave of
-
Teva launches first inhaled antipsychotic in US
Medivir sub-licensed rights to the product in Nordic countries last September.
More from news
Approximately 2 fully matching, plus 18 partially matching documents found.
Latest Intelligence
-
The global antibiotic crisis: a 2020 perspective
The MET-X programme was in-licensed from Swedish company Medivir and is focused on a novel small molecule that, when used in combination with β-lactam antibiotics, restores their function.
-
Deal Watch November 2016
licence. 115.5. Medivir | BioPhausia/ Karo Pharma. business with 13 established pharma drugs.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
MISSION appoints Paul Wallace as chief business officer
Joins from Medivir where he was executive VP and head of business development. ... During his time at Medivir, he played a key role in the execution of over 25 partnership deals, eight products were taken into clinical development and two drugs were
-
Medivir names new CEO
Niklas will in particular be able to contribute and strengthen Medivir in the important areas of strategic business development and commercialisation.”. ... An update of Medivir's strategic plan is the number one priority, and work on this is already
More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Sanofi's frexalimab shows promise in relapsing forms of MS
- Amgen reports positive results for Otezla in psoriatic arthritis
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- How an AI algorithm might save your life
- Navigating patients step by step on their clinical trial journey
- Innovative Trials responds to national recommendations to tackle UK clinical trial decline
- AstraZeneca shares positive phase 3 results for Tagrisso in lung cancer
- BMS presents positive four-year results for Opdivo combination in lung cancer
- Tuberculosis – why it remains a major global public health challenge
- Whitepaper: Closing the gap with compelling healthcare communications
No results were found
PMHub
COUCH Health
We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...
Latest intelligence
- Tuberculosis – why it remains a major global public health challenge
- Innovative collaboration is required to address the major public health challenges around TB and expedite drug development...
- Whitepaper: Closing the gap with compelling healthcare communications
- Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
